Community Research and Development Information Service - CORDIS

Results 1 - 10 of 194
Order by: Results/page:
12 3 4 5 6 7 8 9 10 > >| 
Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood
ID: 115749
Start date: 2015-01-01, End date: 2019-12-31
Blood-based biomarkers such as Circulating Tumor Cells (CTCs), circulating free tumor DNA (cfDNA) and microRNAs (miRNAs) have the potential to improve the development of personalized medicines for cancer patients. This is of particular importance when biopsies of the primary ...
Programme: FP7-JTI
Record Number: 203725
Last updated on: 2017-04-24
Combatting Bacterial Resistance in Europe - Carbapenem Resistance
ID: 115620
Start date: 2015-03-01, End date: 2020-02-28
Multi-drug resistant Gram-negative bacteria (MDR-GNB): the ultimate challenge! Antibiotic resistance is a global public health concern recently elevated to the top three threats identified by the WHO, and subject of numerous national and international government activities. A...
Programme: FP7-JTI
Record Number: 203671
Last updated on: 2017-04-24
European Gram Negative Antibacterial Engine
ID: 115583
Start date: 2014-02-01, End date: 2020-01-31
The intensive use and misuse of antibiotics has resulted in some level of antibiotic resistance in essentially all human bacterial pathogens. There is a growing concern that the loss of therapeutic options will present us with a post-antibiotic era where present and future me...
Programme: FP7-JTI
Record Number: 203716
Last updated on: 2017-04-24
European Bank for induced pluripotent Stem Cells
ID: 115582
Start date: 2014-01-01, End date: 2017-12-31
EBiSC is designed to address the increasing demand by iPSC researchers for quality-controlled, disease-relevant research grade iPSC lines, data and cell services. Its goal is to demonstrate an operational banking and distribution service of iPSC lines after 3 years and to est...
Programme: FP7-JTI
Record Number: 203673
Last updated on: 2017-04-24
Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases
ID: 115565
Start date: 2014-02-01, End date: 2019-01-31
We concur to the IMI on “Reclassification of SLE, connective tissue diseases and RA” call by presenting a proposal aimed at using the power of OMICs, and bioinformatics to identify new classifications for diseases known to share common pathophysiological mechanisms. Such know...
Programme: FP7-JTI
Record Number: 203714
Last updated on: 2017-04-24
Combatting Bacterial Resistance in Europe
ID: 115523
Start date: 2013-01-01, End date: 2021-02-28
The emergence of Antibiotic-resistant bacteria (ARB) is a global problem, having recently been elevated to the top three threats identified by the World Health Organisation (WHO), and subject of numerous national and international government activities, including the Trans-At...
Programme: FP7-JTI
Record Number: 203711
Last updated on: 2017-04-24
Applied Public-Private Research enabling OsteoArthritis Clinical Headway
ID: 115770
Start date: 2015-06-01, End date: 2020-11-30
The problem: finding the right patient for the right treatment Despite a large and growing disease burden in osteoarthritis (OA), many pharmaceutical companies have de-emphasized or even abandoned OA drug development due to perceived hurdles. Crucial in this is the lack of ap...
Programme: FP7-JTI
Record Number: 203727
Last updated on: 2017-04-17
Unrestricted Leveraging of Targets for Research Advancement and Drug Discovery
ID: 115766
Start date: 2015-03-01, End date: 2020-02-29
ULTRA-DD (Unrestricted Leveraging of Targets for Research Advancement and Drug Discovery) will be an European-wide, highly collaborative and inclusive consortium, to validate new targets for drug discovery by (1) generating high quality research tools, with an emphasis on che...
Programme: FP7-JTI
Record Number: 203728
Last updated on: 2017-04-17
Intelligent Assessment of Pharmaceutical in the Environment
ID: 115735
Start date: 2015-01-01, End date: 2018-12-31
Active pharmaceutical ingredients (APIs) can be released to the natural environment during the manufacturing process, following use by patients or when unused medicines are disposed of. As APIs are biologically active compounds concerns have been raised about the potential ef...
Programme: FP7-JTI
Record Number: 203722
Last updated on: 2017-04-17
Recognising Adverse Drug Reactions
[PROJECT] WEB-RADR - Recognising Adverse Drug Reactions
ID: 115632
Start date: 2014-09-01, End date: 2017-08-31
WEB-RADR is a consortium of leading experts in pharmacovigilance from regulatory agencies, research, academia and patient support groups. Together with EFPIA partners our aims will be to set policy & guidance and deliver robust information technology tools to address the pote...
Programme: FP7-JTI
Record Number: 203719
Last updated on: 2017-04-17
12 3 4 5 6 7 8 9 10 > >| 
List retrieved on: 2017-04-28
Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top